A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer

BACKGROUND: The mean 5–6-month survival after failed standard chemotherapy for metastatic colorectal cancer (mCRC) necessitates more effective treatments for refractory mCRC. For untreated mCRC, S-1 + oral leucovorin (SL) therapy offers promising results without severe toxicity. The ML18147 trial de...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Kazuhisa, Taniguchi, Hiroya, Komori, Azusa, Narita, Yukiya, Nitta, Sohei, Nomura, Motoo, Kadowaki, Shigenori, Takahari, Daisuke, Ura, Takashi, Andoh, Masashi, Muro, Kei, Mori, Keita, Igarashi, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550068/
https://www.ncbi.nlm.nih.gov/pubmed/26311588
http://dx.doi.org/10.1186/s12885-015-1606-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550068/
https://www.ncbi.nlm.nih.gov/pubmed/26311588
http://dx.doi.org/10.1186/s12885-015-1606-1

Ejemplares similares